We enrolled 15 obese individuals (mean BMI 45±5.4 kg/m2) undergoing gastric bypass surgery. Before and 6 months after surgery, subjects were admitted to the clinical research center and administered a large‐volume intravenous saline challenge. Echocardiography and serial blood sampling were performed. From the pre‐operative visit to 6 months after surgery, subjects had a mean BMI decrease of 27%. At the 6‐month visit, N‐terminal pro‐atrial NP (Nt‐proANP) levels were 40% higher before, during, and after the saline infusion, compared with levels measured at the same time points during the pre‐operative visit (P<0.001). The rise in Nt‐pro‐ANP induced by the saline infusion (≈50%) was similar both before and after surgery (saline, P<0.001; interaction, P=0.2). Similar results were obtained for BNP and Nt‐proBNP; resting concentrations increased by 50% and 31%, respectively, after gastric bypass surgery. The increase in NP concentrations after surgery was accompanied by significant decreases in mean arterial pressure (P=0.004) and heart rate (P<0.001), and an increase in mitral annular diastolic velocity (P=0.02).

Serum IGF-1 levels remained relatively constant over the dosing period with no apparent differences between treatment groups. Fasting plasma glucose and serum insulin levels remained unchanged throughout the treatment period. Furthermore, no changes in any of the OGTT parameters were observed from day 1 to day 7 of treatment. There were no study related clinically significant findings in the safety related laboratory tests, vital signs, or ECG measurements.
Cerebrolysin—also known as FPE 1070—is a synthetic nootropic drug. Nootropic drugs are substances that enhance cognitive functions such as memory, creativity, and motivation in otherwise healthy individuals. This peptide is extremely small, allowing it to penetrate the blood-brain barrier and act directly on the neurons of the central nervous system. Cerebrolysin has been found to improve the metabolic activity of brain tissue, shield neurons from harmful substances, and stimulate the peripheral and central nervous systems. In addition to its utility as a nootropic substance, the drug has potential as part of a treatment plan addressing Alzheimer’s disease, stroke, and moderate to severe head injury.
You’ve already learned that sufficient protein intake (above 0.5g/lb of body weight) can assist with adequate IGF-1 and growth hormone production. Whey protein provides your body with a complete profile of necessary amino acids, including leucine. Leucine is an amino acid that promotes greater muscle protein synthesis and assists the body while gaining lean muscle mass and losing fat tissue simultaneously.

The evidence so far suggests that there may be some effect on cartilage and bone densities, and it is correlated with weight loss. I understand that there is no evidence to suggest that it stimulates the release of IGF-1, which is the mechanism via which growth hormone gets most of its purported performance enhancing effects (i.e. muscle bulk). Whilst this is a decent list of things to test if one is considering AOD9604 as simply a variant of growth hormone, it is by no means exhaustive of all the mechanisms via which a drug can enhance athletic performance. The evidence thus far suggests that AOD9604 could be performance enhancing, but there is nothing I would hang my hat on. That is why I maintain that Dank is more sorcerer than scientist.
Causing one to be " hungry as a wolf " and having a strong gastric motility, this 1er injectable peptide is interesting for fitness practitioners who may require support to finish their carefully prepared meals. This sudden increase in appetite that occurs around 20 minutes after the injection is related to the fact that GHRP-6 stimulates the release of a digestive hormone, Ghrelin, which is designed to cause hunger pangs. This makes it a valuable ally in weight gain treatments , which is important.
The company which developed it, Metabolic Pharmaceuticals, did have a small early study done which showed a small amount of fat loss at 1 mg per day but not really any other dosing. Measured effect was less at higher doses. In total the company did at least six studies. According to the lead researcher of five of the studies, Dr Gary Wittert, results were uniformly negative.
In our study, the rapid recovery from lameness (11 days) in the group that received AOD9604 and HA injection suggests that an early anti-inflammatory and pain-relieving effect could be induced before the tissue repair observed at the end of the treatment period (35 days). This result may be explained by the pain-relieving effects of GH [30]. The intra-articular injection to the human knee using ultrasound guidance notably enhances the accuracy compared with injection using anatomical guidance [31–33]. Until recently, intra-articular injections to the rabbit knee using ultrasound guidance have rarely been reported [34]. In our study, intra-articular injections were performed using ultrasound guidance to identify the correct trajectory for needle placement in the knee joint, as the rabbit knee joint is smaller than that of humans.
Yes, Ipamorelin can help you lose weight. But, if you are not exercising, and aren’t eating well, it can only do so much. There is no magical supplement which will undo laziness and a horrible diet – keep this in mind. When using it for fat loss, make sure you are exercising. Doing so will naturally increase weight loss results, as you are going to burn more calories, along with the caloric deficit you are already on, for greater results. Further, your diet matters. If you are eating 5000 calories of junk per day, no supplement will help you lose weight – no matter how potent it claims to be!
In vitro and in vivo investigations revealed a specific region within the hormone molecule that is responsible for the molecular events associated with lipid metabolism [18, 24, 25]. AOD9604 is a peptide fragment of the C-terminus or lipolytic domain of hGH (hGH177-191), with an additional tyrosine residue at the N-terminal end for stabilization. In vitro and in vivo experiments have shown similar effects of AOD9604 and hGH on lipid metabolism when chronically applied to mice [20, 21]. Interestingly, AOD9604 mimics the effect of hGH on lipid metabolism, without having growth promoting or pro-diabetic effects. The safety and tolerability of AOD9604 has been studied in the human clinical trials described in this paper.
Prior to commencement of active treatment, 48.4% of subjects experienced at least one AE. The body system organ classes with the highest incidences of events (> 10%) were the nervous system (17.5%; mainly headache, 14.5%), infections and infestations (15.9%, mainly nasopharyngitis and upper respiratory tract infection, 4.0%), gastrointestinal system (12.4%, mainly diarrhea 3.2%) and musco-skeletal and connective tissue disorders (12.0%, mainly back pain, 4.0%), 32.9% of subjects experienced mild AEs, 38.6% experienced moderate AEs and 36 (7.2%) patients experienced severe AEs. The intensity of AEs was similar across all treatment groups. None of the AEs were deemed to be definitely related to the study treatment.
We organise and run biennial international scientific conferences, satellites and support local state meetings. Our meetings are designed to be in the fashion of the relaxed Gordon conference – with about 200 delegates and with a friendly and a highly participatory atmosphere. We also have a strong commitment to our early career researchers and students.
 Please note, as this is a prescription item, one of our doctors will review your profile and approve your order if appropriate. A prescription will only be issued in accordance to the prescribing guidelines, and for use that strictly complies to the doctor’s directions and dosage. This script will be forwarded to our dispensary team, and placed in our secure, internal records.
CJC 1295 can be compounded in two forms (DAC and non-DAC). Drug affinity complex (DAC) prevents enzymatic degradation thus increasing the half-life. Consequently CJC 1295-DAC can be dosed as a single weekly injection. Administration of CJC 1295-DAC provides a GHRH-like stimulation around the clock. A potential drawback when using a weekly protocol can be attributed to ineffective GHRH stimulation when the body is due for a GH spike (usually 1:00am). This is referred to as a GH-bleed and the overall result is inferior to using CJC 1295-NON-DAC daily for 5 days out of 7. Therefore using CJC 1295-NON-DAC daily (between 6-8pm) provides a more effective GH spike at 1:00am.
One of the biggest concerns many of us have as we get older is: weight management. Maintaining a healthy weight is a lifelong struggle for many and can get harder as we get older. In fact, statistics show that 70% of American adults are overweight, and half of those adults are obese. We need to find ways to lose weight in a healthy manner, and more importantly keep off the weight, long-term. Ongoing research about collagen, a natural and unique type of protein, shows that collagen supplementation just might be the key in your journey to stay at a healthy weight and better your health.
A study research coordinator screened charts for eligibility from a pool of patients who were referred to the weight center of the Massachusetts General Hospital for Roux‐en‐Y gastric bypass surgery. Eligible patients were informed about the details of the research protocol, including the need for 2 saline infusion visits at the Clinical Research Center (CRC) 6 months apart. A study physician investigator verified the medical history of study participants including the use of medications at the time of the saline protocol visit. The subjects were asked to keep a detailed diary of all the food and beverages consumed for the 48 hours prior to each study visit to estimate their nutritional status.
In lean animals, neither AOD9604 nor hGH had any effect on epididymal white adipose tissue mass or expression ofβ 3-AR RNA, indicating that in lean animals, this fat tissue is not a major target for these drugs in this study. In contrast, the mass of BAT in lean animals was reduced by both hGH and AOD9604, and β3-AR RNA expression was increased by both these compounds. This could possibly suggest that the increased expression of β3-ARs in brown adipocytes sensitizes catecholamines to dissipate heat.
In ob/ob mice, both AOD9604 and hGH reduced both white and brown adipose tissue mass and increased β3-AR RNA expression. This suggested that an elevation inβ 3-AR RNA expression is associated with increased fat metabolism and a reduction in the fat tissue mass in the ob/ob mouse model. Obese mice have lower levels ofβ 3-AR expression in their adipose tissues than lean mice, shown in this study and others (14). The ability of AOD9604 and hGH to increase the level ofβ 3-AR RNA expression in obese mice to a level that is comparable to those in lean mice is an exciting finding. However, it must also be considered that both hGH and AOD9604 may influence the expression of other members of the adrenergic pathway, such as the β1-ARs, hormonesensitive lipase, and signaling proteins, which are all expressed in adipose tissue and associated with lipolysis. The importance of the change inβ 3-AR expression with AOD9604 and hGH in humans is not established and will depend on the use of potent and selectiveβ 3-AR agonists that are active at the human receptor.
Prof. Gary Wittert, Adelaide-based Principal Investigator on the study, said: “As the world’s first drug with a metabolic mechanism of action AOD9604 could occupy a unique position among the options available to doctors for the management of obesity. It is pleasing that the invention and its development from the laboratory bench has been an all–Australian effort.”

AOD9604, a synthetic fragment of hGH consisting of the amino acid residues 177–191 with the addition of a tyrosine residue to the N-terminus was prepared with solid-phase synthesis procedure and purified with reverse-phase HPLC methodology in our laboratories (13). The structure of the peptide analog was verified with mass spectrometry and amino acid analysis. The hGH was a gift of Professor Michael Waters (University of Queensland, Brisbane, Australia). BRL37344 (β3-AR agonist) was a gift from Dr. Jon Arch (SmithKline Beecham, Harlow, UK).
Application would result in all current OTC paracetamol/ phenylephrine products being up-scheduled to S3. Applicant’s justification for changing current combination products from exempt or S2 to S3 is on theoretical basis only, and no evidence provided of clinical risk. Pharmacokinetic study found that co-administration of paracetamol with phenylephrine increased plasma phenylephrine levels – applicant says this has potential for cardiac safety risk in susceptible patients.

The scheduling of paracetamol and caffeine when combined in a compound analgesic as the only two active ingredients was amended from Schedule 4 to Schedule 2 by the NDPSC at its 50th Meeting in June 2007. Evidence reviewed by the Committee at that time conclusively demonstrated that the key ingredient in terms of analgesic overuse and nephropathy was phenacetin and not caffeine. It was agreed that the indications for use, safety profile and potential for misuse met the criteria for a Schedule 2 medicine.
IGF-1 is so named because of its close resemblance to insulin. Because IGF-1 is so similar to insulin, it interacts with insulin receptors on the surface of your cells, produces some of the same effects as insulin and even magnifies the effect of insulin. For example, one primary effect of both excess insulin and excess IGF-1 is hypoglycemia (low blood glucose). When you workout for a long time (longer than about one hour) your liver increases its release of IGF-binding protein (IGFBP-3) to prevent the onset of hypoglycemia that would otherwise happen as a result of the increased release of IGF-1 that occurs during training.
Diet Doc’s certified medical weight loss doctors can help you discover the benefits of Ipamorelin as part of a personalized medical weight loss plan. Getting started with a Diet Doc medical weight loss plan is easy – just call us or send us some information to schedule a virtual or phone evaluation with a doctor. We’ll build your personalized weight loss program and put your medication in the mail that same day, so you can start losing weight as soon as possible. Using Ipamorelin requires a baseline and semi-annual IGF1 lab test to ensure levels are low enough to begin treatment, and that they don’t become too high during treatment. Get started today!
In June 2010, the National Drugs and Poisons Schedule Committee (NDPSC) considered the scheduling of paracetamol in combination with ibuprofen. Paracetamol preparations containing 500 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine, effervescent agents or guaiphenesin) in packs of 25 or less were exempt from scheduling. However, when these preparations were combined with another therapeutically active ingredient they became Schedule 2. The NDPSC considered that the Schedule 2 entry remained appropriate, but noted the possibility that more robust evidence of additional risk could come to light through any application for product approval with the Therapeutic Goods Administration. The delegate confirmed the NDPSC's decision and the reasons for the decision in August 2010.
The β3-AR and actin primers were intron spanning to potentially reveal contaminant genomic DNA (none observed). Reverse primers were labeled before the PCR in a reaction mixture containing 120 pmol oligonucleotide, 70 μCi[γ -33P]ATP (Bresagen, Adelaide, Australia), 1× One-Phor-All Plus buffer (Pharmacia Biotech, Uppsala, Sweden) and 20 U T4 polynucleotide kinase (Pharmacia Biotech) in a volume of 40 μl. Following incubation at 37 C for 30 min, reactions were diluted to 100 μl with H2O and heated at 90 C for 2 min.
Cerebrolysin—also known as FPE 1070—is a synthetic nootropic drug. Nootropic drugs are substances that enhance cognitive functions such as memory, creativity, and motivation in otherwise healthy individuals. This peptide is extremely small, allowing it to penetrate the blood-brain barrier and act directly on the neurons of the central nervous system. Cerebrolysin has been found to improve the metabolic activity of brain tissue, shield neurons from harmful substances, and stimulate the peripheral and central nervous systems. In addition to its utility as a nootropic substance, the drug has potential as part of a treatment plan addressing Alzheimer’s disease, stroke, and moderate to severe head injury.
One of the important reasons we consume protein is that it helps to keep our bodies full. While many people use protein powders for this purpose, a lot of protein powders are filled with fillers or unnatural additives. Collagen protein, on the other hand, is a clean protein - in its pure form, it has no additives or sweeteners - that can help keep you full and promote satiety. Several studies have focused on the benefits of consuming collagen in helping people who are trying to lose weight. In a study assessing hunger hormones in 10 obese patients and 12 patients of normal weight, researchers found that the intake of gelatin (a substance derived from collagen itself) actually increased the satiety hormone, which means the subjects were more likely to adhere to their weight loss diets(1). If you could maintain satiety longer, you may be on the road to effective weight loss simply by reducing your own hunger.

Results: AOD 9604 had no effect on serum IGF-1 levels, which confirms the hypothesis that AOD 9604 does not act via IGF-1. Results of oral glucose tolerance test demonstrated that, in contrast with hGH, AOD 9604 has no negative effect on carbohydrate metabolism. There were no anti-AOD 9604 antibodies detected in any of the patients selected for antibody assay. In none of the studies did a withdrawal or serious adverse event occur related to intake of AOD 9604.
Both AOD9604 and, to a greater extent, hGH increase body weight in lean mice, compared with saline-treated animals. This is in the absence of an increase in fat mass, which suggests an increase in lean body mass occurs with these compounds. This supports previous work with hGH in rodents and humans (17). Both compounds have also been previously shown to reduce body weight and adiposity in obese mice (11). The effects of hGH and AOD9604 occur without significant changes to caloric intake. It has been reported that hGH increases, reduces, or does not change food intake in which the differences are attributed to variations in hGH preparations, concentrations, and animals used between different laboratories.
Thymosin alpha-1 (T α 1) is a peptide, or small protein, consisting of 28 amino acids. T α 1 is produced naturally by the thymus gland. The thymus is located behind the sternum and between the lungs, and is where immune cells known as T cells mature and are released, prompted to do so by the T α 1 peptide. T cell production and action within the body is vital to adaptive immunity—the mode by which immune cells are able to recognize and eradicate foreign invaders.
200 to 300 mcg is typically the daily dosage which is recommended for the typical Ipamorelin user. It can be taken anytime during the day but is advisable to be used in the morning, as it will help you achieve the best results in such cases. Regardless of when you start your dosage, it is important to ensure you are taking it at the same time each day. And, for new users, it is best to stick to a one-a-day cycle.
As it is not yet approved for use in this country (or any other), it should always have been considered banned under the S0 category, which states that any pharmacological substance that is not addressed by any of the subsequent sections of the Prohibited List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited.
You can add CJC-1295 DAC at 2mg once per week (or 300mcg each day along with your HGH Frag 176-191 injections - they can be mixed in the same syringe without any issues). You should take a break from CJC-1295 DAC every few months to give your pituitary gland a rest at which time you can continue to use HGH Frag 176-191 on its own, or you can substitute the CJC-1295 DAC with the short acting Modified GRF 1-29 at 100-300mcg per day (split into injections of 100mcg).
In order to demonstrate safety, several human studies were performed with AOD9604 (supplementary data): 1). METAOD001: A Phase I (double-blind, placebo-controlled, dose escalation) safety study with doses (ranging from 25 to 400 µg/kg AOD9604) administered intravenously to 15 healthy adult male volunteers presenting with a BMI between 24 and 30 kg/m2. A single dose of recombinant hGH (0.12 international units/kg) was administered intravenously as positive control. 2). METAOD002: A Phase IIa (double-blind, placebo-controlled 4 × 4 Latin Square design) safety study with single doses (25, 50 and 100 µg/kg AOD9604) administered intravenously to 23 healthy clinically obese males presenting with a BMI ≥ 35 kg/m2. 3). METAOD003: A Phase IIa (double-blind, placebo-controlled 4 × 4 Latin Square design) safety study with single doses (9, 27 and 54 mg AOD9604) administered orally (capsules) to 17 healthy, clinically obese males presenting with a BMI ≥ 35 kg/m2. 4). METAOD004: A Phase IIa (double-blind, placebo-controlled, dose escalation) safety study with multiple daily doses (9, 27 or 54 mg AOD9604) administered orally (capsules) for seven days in 36 healthy clinically obese males presenting with a BMI ≥ 30 kg/m2. 5). METAOD005: A Phase IIb (randomized, double-blind, placebo-controlled) study to assess the efficacy (reduction in body weight), safety and tolerability of 12 weeks treatment with daily doses (1, 5, 10, 20 or 30 mg AOD9604) administered orally (capsules) in 300 healthy, clinically obese males, and females of non-child bearing potential, with a BMI ≥ 35 kg/m2. 6). METAOD006: A Phase IIb, randomized, double-blind, placebo-controlled study to assess the efficacy (reduction in body weight), safety and tolerability of 24 weeks treatment with different doses of AOD9604 tablets (0.25 mg, 0.5 mg, 1 mg, or placebo) in 502 obese adults.
AOD9604, a synthetic fragment of hGH consisting of the amino acid residues 177–191 with the addition of a tyrosine residue to the N-terminus was prepared with solid-phase synthesis procedure and purified with reverse-phase HPLC methodology in our laboratories (13). The structure of the peptide analog was verified with mass spectrometry and amino acid analysis. The hGH was a gift of Professor Michael Waters (University of Queensland, Brisbane, Australia). BRL37344 (β3-AR agonist) was a gift from Dr. Jon Arch (SmithKline Beecham, Harlow, UK).
The test substance was either administered intravenously (studies METAOD001 and METAOD002) or as a capsule/tablet. The hexadecapeptide AOD9604 was produced under cGMP conditions by PolyPeptide Laboratories (Torrance, CA, USA). For studies 1 and 2, the product was supplied in a lyophilized form and reconstituted before usage with the designated volume of sterile water for intravenous injection. The capsules/tablets were manufactured using a common excipient mix (Capsules: Mannitol, PEG3350 (in studies METAOD003, METAOD004 and METAOD005)); or Tablets: L-Arginine Free Base, Microcrystalline Cellulose, Fumed silica, Magnesium Stearate (in study METAOD006)).
Very tough to say. I am not a doctor and this is not to be taken, interpreted or construed as medical advice. Please talk with a licensed medical professional about this. These are just my own personal thoughts and not a prescription or a diagnosis or any form of health care whatsoever. I could possibly help but would need to see your health history, blood, biomarkers, etc. I'd be happy to help you via a personal one-on-one consult. Just go to https://bengreenfieldfitness.com/coaching. and then choose a 20 or 60 minute consult, whichever you'd prefer. I can schedule ASAP after you get that.
It is well known that hGH is associated with increased IGF-1 levels. IGF-1 may have a variety of undesirable effects, including an increase in cancer risk [22, 23]. In the studies discussed herein, IGF-1 levels were monitored in all long-term studies but did not reveal clinically significant differences between dose groups or placebo. Therefore the 5 SAEs that occurred in the 12 week treatment study (three in the AOD9604 20 mg group (basal cell carcinoma, moderate lipoma and squamous cell carcinoma), one in the 10 mg group (malignant melanoma) and one in the 5 mg group (breast cancer)) could not be attributed to increased IGF-1 levels. The Principal Investigator considered none of the reported SAEs to be “possibly”, “probably” or “definitely related” to the study medication. The rationale behind this judgment was that none of the cancer forms occurred in the highest dosage group (30mg AOD9604/day), therefore a dose effect can be excluded. Further examination of the SAE cases indicated that these subjects had neglected their personal medical care for a longer period of time, so that the higher incidence of cancer may well have occurred due to the natural incidence rate of cancer events in the population.
Example 1 - Night Time Injection (recommended) ◦Ensure you do not eat or drink anything containing calories within three (3) hours of going to bed (with the exception of water, diet sodas, coffee/tea with artificial sweeteners). ◦Take your HGH Frag 176-191 injection just before getting into bed and your body will therefore be burning stored fat for the duration of your sleep. ◦If possible, do some cardio first thing in the morning and wait as long as possible before having breakfast to allow the fat burning to continue throughout the morning/day.

When using any GHRH, it should always be remembered that positive results cannot be achieved overnight. These compounds act steadily over time, and the best results can be achieved slowly, and with a nutritious diet and a proper exercise regime. Also, these peptides are not sex-specific, so they do not have any androgenic effects. They can be used by women in the same dosages that men do.
Injections of other compounds along with IGF-1 (which is a popular practice) can also cause serious health issues. The idea is that after an user administers a GHRP (like Ipamorelin) along with IGF-1, a selective pulse is then sent that stimulates the hypothalamus and pituitary to release even more growth hormone. But this may result in an eventual negative feedback loop that leaves you unable to produce your own growth hormone and stuck on injections forever. GHRP and synthetic HGH use has also been shown to cause joint pain, huge spikes in cortisol, excessive hunger, and splitting headaches.
I have not used IGF-1 but I have used a stack of Ipamorelin and CJC 1295 no DAC. I did not do any lab tests before, during or after but definitely noticed increased fat loss and better sleep. I was not trying to increase muscle so there was no change to speak of for me. But you are not recommending their use even without IGF-1, is that correct? I do not compete in anything so WADA is not a concern.
Simply Vital is an online service that acts as an agent between the customer and "Initially we were inundated by men wishing to find a way to add muscle quickly, but now in excess of 60 per cent of our weekly orders are women wanting products to help with results ranging from fat loss and anti-ageing to general well-being," says owner Michael Abdallah.
×